HOME >> MEDICINE >> NEWS
Novartis announces collaboration with Bayer for EMSELEX

Basel, 17 December 2004 Novartis Pharma AG announced today the start of a collaboration between Novartis Pharma GmbH and Bayer Vital AG for the commercialization and distribution of EMSELEX (darifenacin hydrobromide), 7.5 mg and 15 mg in Germany. The collaboration is effective following an agreement between Bayer Vital AG and Novartis Pharma GmbH. EMSELEX, a new once-daily M3 selective receptive antagonist (M3 SRA) recently received Marketing Authorization from the European Commission in 25 European member states, plus Norway and Iceland for the treatment of overactive bladder (OAB).

"Bayer Vital has significant expertise of the German urology market, so collaborating with them helps to ensure that EMSELEX will reach physicians quickly and ultimately benefit patients who suffer from overactive bladder," said Kurt Graves, Chief Marketing Officer, Novartis Pharma AG. "EMSELEX is a new effective drug for the treatment of OAB that is selective for the M3 receptors in the bladder, with proven efficacy, good tolerability and with a well established central nervous system and cardiovascular safety profile." Under the terms of the collaboration, Novartis remains the owner of the marketing authorization for darifenacin, while Bayer Vital gains exclusive commercialization rights for EMSELEX in Germany.

About EMSELEX
EMSELEX is a once-daily M3 selective receptive antagonist (M3 SRA) oral treatment that works by selectively inhibiting the M3 receptor, the primary mediator of detrusor contraction, whilst sparing the M1 and M2 receptors that are located in various body organs, including the brain and heart. EMSELEX has been shown to effectively reduce the number of weekly incontinence episodes by up to 77% versus placebo.1 Additional clinical trials comparing EMSELEX with placebo showed that EMSELEX does not impair cognitive function and has a cardiovascular safety profile similar to placebo.

To date, 98 clinical trials with EMSELEX ha
'"/>

Contact: Eric Althoff
eric.althoff@pharma.novartis.com
41-61-324-6392
Ketchum
17-Dec-2004


Page: 1 2 3

Related medicine news :

1. Dr. Judah Folkman honored with American Heart Association/Novartis award
2. Drs. Gerald DiBona and John Hall receive American Heart Association/Novartis award
3. Novartis receives FDA approval for Starlix, a new treatment for type 2 diabetes
4. Novartis receives FDA approval for LESCOL XL 80 mg
5. The Gerontological Society of America announces Hartford Fellowship recipients
6. TB Alliance announces new drug discovery program with GlaxoSmithKline
7. ASGE announces grant recipients in annual research awards program
8. American College of Chest Physicians announces new Critical Care Institute
9. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
10. Department of Energy announces new agreement with USC, national labs and private company
11. ACP announces international medical fellowship

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... ... Houston Life coach, Rashad Garrett, has thrown a lifeline to those struggling with mental ... Faith Of A Mustard Seed (FOAMS). , The global pandemic has caused a drastic ... Federal Agency emergency helpline dedicated to helping people in emotional distress registered more than ...
(Date:7/2/2020)... YORK (PRWEB) , ... July 02, 2020 , ... ... New York plastic and cosmetic surgeons, with medical offices located in Staten Island, Huntington ... will be relocating to a beautifully designed medical suite at The Parlor NYC at ...
(Date:7/2/2020)... ... July 02, 2020 , ... The Coronavirus (COVID-19) pandemic ... work. In conjunction with the American Dental Association and Centers for Disease Control ... , Due to safety concerns, the announcement sparked hesitancy among some hygienists, ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... development of psychedelics and analogues, announces its core executive team. The co-founders Drs. ... drug discovery, novel formulations, and as distinguished researchers within the cannabis industry. They ...
(Date:6/28/2020)... (PRWEB) , ... June 26, 2020 , ... ... call for participation in the revision and redesignation of the ANSI/APSP/ICC-7 2013 American ... Tubs, and Catch Basins. PHTA is seeking member participation on the PHTA-7 Standard ...
Breaking Medicine News(10 mins):
(Date:7/2/2020)... ... July 02, 2020 , ... Gulf Coast Pharmaceuticals Plus ... donation of more than $190,000 in personal protective equipment (PPE) to the Virginia ... extreme medical shortages continue to plague the nation’s communities and healthcare facilities, GCPP ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... ever, Stratodesk NoTouch OS is available on NComputing devices. Thanks to fantastic new ... and Stratodesk have formed a new partnership that will make the full Stratodesk ...
(Date:6/25/2020)... ... 2020 , ... R3 Medical Training announced today it is now enrolling for ... The first course is August 6-7, 2020 in San Diego and the second is ... Virtual Live Stream option. , The two day agenda for each course is identical, ...
Breaking Medicine Technology:
Cached News: